Latest news

Takeda, Zinfandel ax Alzheimer’s test for pioglitazone, chalking up another AD fail

By Ben Adams
Japanese Big Pharma Takeda and U.S. partner Zinfandel Pharmaceuticals have decided to give up and stop testing a 20-year-old diabetes medicine that they hoped could work as a new Alzheimer’s therapy.  
The details from the brief update: The so-called "Tomorrow" trial has been pulled after the pair got their hands on a planned interim futility analysis, which showed that Actos (pioglitazone), already approved as a diabetes medicine (and as a generic), had an “an inadequate treatment effect […] in delaying the onset of mild cognitive impairment due to Alzheimer’s disease.”
Read: It didn’t work, although they added it had no safety issues.
Read more.